China
Africa
Explore chapters and articles related to this topic
Myelodysplastic Syndromes
Published in Wojciech Gorczyca, Atlas of Differential Diagnosis in Neoplastic Hematopathology, 2014
During normal maturation, increasing expression of CD11b and CD16 is seen in final stages of maturation and neutrophils show the brightest expression (Figure 32.8). The expression of CD13 is high in blasts, decreases during promyelocytic and myelocytic stages, and starts to increase again as the cells progress from bands to segmented forms. CD10 and CD16 are expressed by mature granulocytic cells and the expression of CD11b starts to appear in late myelocytes and is highest in bands and neutrophils.
Overview of Angiogenesis: Molecular and Structural Features
Published in Robert J. Gropler, David K. Glover, Albert J. Sinusas, Heinrich Taegtmeyer, Cardiovascular Molecular Imaging, 2007
Arye Elfenbein, Michael Simons
In contrast to the broad vascular expression pattern of phosphotidyl serine phospholipids, the membrane-bound metalloprotease known as aminopeptidase N, or CD13, has received attention on account its specific association with angiogenic endothelial cells (51). Aminopeptidase N has been shown to inactivate or activate small, extracellular, bioactive peptides by cleaving their terminal residues. However, its particular regulatory role in angiogenesis has been characterized in several models, while the involved substrates remain elusive. Furthermore, the recent discovery that CD13 inhibitors attenuate the progression of tumor angiogenesis (52) augments this molecule’s candidacy as a specific marker of novel vessel growth.
Polymeric Conjugates for Angiogenesis-Targeted Tumor Imaging and Therapy
Published in Mansoor M. Amiji, Nanotechnology for Cancer Therapy, 2006
Amitava Mitra, Anjan Nan, Bruce R. Line, Hamidreza Ghandehari
Aminopeptidase N (APN) (also known as CD13) is a membrane, spanning 140 kD cell surface protein61 that plays a role in tumor invasion.62,63 APN has been successfully targeted using peptides containing an Asn-Gly-Arg (NGR) motif.54 NGR peptides have been used to deliver chemotherapeutic agents64 and pro-apoptotic peptides65 to tumor cells. In a murine breast carcinoma xenograft model, a NGR-doxorubicin conjugate significantly decreased metastasis to lymph nodes and substantially increased survival compared to free doxorubicin. In addition, the conjugates were less toxic to the liver and heart as compared to the free drug.64
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report
Published in Current Medical Research and Opinion, 2020
Jing Cheng, Yaping Liao, Ting Bin, Juan OUYang, Shaoqian Chen, Xueyan Chen, Waiyi Zou
AML is a hematopoietic stem cell malignancy characterized by clonal expansion of myeloid blast cells in the bone marrow, blood and extramedullary tissue6. According to the World Health Organization (WHO) classification, AML M5 is the subtype of AML with two distinct morphologic subcategories, M5a and M5b7. The patient was a 34-year-old male when diagnosed with M5b AML in 2011. Clinical features were not different from other types of AML but primitive myeloid cells accounted for 86%. The symptoms of anemia were serious because of strongly increasing WBC (51.43 × 109/L) and decreasing Hb (59 g/L) and PLT (32 × 109/L). Flow cytometry analysis revealed that leukemic blasts were positive for CD117, CD13, CD33, CD15, CD56, CD2, and human leukocyte antigen-DR, which were markers for diagnosis of AML according to European Leukemia Net Work Package 108. Conventional cytogenetic analysis showed no karyotype abnormalities, and AML with cytogenetic normal (CN) accounted for 40–50% of all adult AML9. MLL rearrangement positive was detected in this case, which is a balanced rearrangement of AML10.
Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy
Published in Drug Delivery, 2021
Mengyu Chen, Yuexin Cui, Wenyan Hao, Yueyue Fan, Jingqiu Zhang, Qianqian Liu, Mingrui Jiang, Yang Yang, Yingzi Wang, Chunsheng Gao
As the CC membrane itself has weak targeting ability, NLCs need to be further modified to improve BBB and BBTB permeability and tumor targeting. Asn-Gly-Arg (NGR) binds specifically to aminopeptidase N (CD13) on endothelial cells during neovascularization. CD13, as a marker of the neovascular system, has a low expression in normal vascular endothelial cells, but is highly expressed in neovascular endothelial cells and some tumor cells (Pierluigi et al., 2018; Valentinis et al., 2019). Therefore, the NGR peptide can target drugs to tumors or angiogenesis tissues, helping the drugs penetrate the BBTB and penetrate and accumulate into tumors.
The mercapturic acid pathway
Published in Critical Reviews in Toxicology, 2019
Patrick E. Hanna, M. W. Anders
Aminopeptidase N (APN, CD13) is a highly multifunctional enzyme that has been termed a “moonlighting” protein. Its regulatory, signaling, receptor, and hydrolytic functions make it an intriguing potential therapeutic target for more than a dozen human cancers, as well as lymphedema, autoimmune disorders, rheumatoid arthritis, and other pathologies associated with APN overexpression (Amin et al. 2018).